Cullinan Therapeutics (CGEM) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cullinan Therapeutics (CGEM) has outperformed Valneva (VALN) over the past year, losing 6.1% versus a loss of 40.1%. Over five years, CGEM leads with a -51.2% price change compared with -91.3% for VALN. Cullinan Therapeutics is the larger company by market cap ($577.1 million vs $490.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | VALN |
|---|---|---|
| Share price | $8.89 | $5.16 |
| Market cap | $577.15M | $490.86M |
| 1-day change | -1.98% | -3.82% |
| YTD return | -14.11% | -41.50% |
| 1-year return | -6.12% | -40.14% |
| 5-year return | -51.21% | -91.34% |
| Forward P/E | — | 4.34 |
| EPS (TTM) | $-3.09 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-219.88M | — |
| 52-week high | $23.19 | $12.18 |
| 52-week low | $8.47 | $4.75 |
| Distance from 52-week high | -61.66% | -57.64% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +285.49% | +137.98% |
| Average volume | 997.14K | 23.10K |
| Shares outstanding | 64.92M | 95.13M |
| Employees | 109 | 620 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEM has outperformed VALN by 34.0 percentage points over the past year.
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
CGEM vs VALN FAQ
Which is bigger, Cullinan Therapeutics or Valneva?
Cullinan Therapeutics (CGEM) is larger, with a market capitalization of $577.15M compared with $490.86M for Valneva (VALN).
Which stock has performed better over the past year, CGEM or VALN?
CGEM returned -6.12% over the past 12 months, compared with -40.14% for VALN (price return, excluding dividends). Past performance does not predict future results.
Are Cullinan Therapeutics and Valneva in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.